Company intelligence / Profile preview

Midifi

New Haven, Connecticut, United Statesmidifi.com ↗

Ownership: Private
Development stage: Other

Overview

Modifi Bio developed a new class of orally delivered small molecules that selectively kill cancer cells by directly modifying their DNA, specifically targeting tumors deficient in the MGMT protein. Their lead compound, KL-50, demonstrated robust anti-tumor activity in preclinical models and showed potential to overcome resistance mechanisms common to existing therapies. The company received significant grant funding and seed investment before being acquired by Merck in October 2024 for $30 million upfront plus up to $1.3 billion in milestone payments[5].

Therapeutic areas: Oncology
Modalities: Small molecule
Industry: Biotech

Partnerships

No major pharma partnerships disclosed prior to acquisition; strong academic collaboration with Yale University.

Beyond the preview

Go deeper on Midifi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Midifi.

Explore the full profile